A STAT3 polymorphism can be used to predict the response to interferon-α in patients with metastatic renal cell cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1599, 2007-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interferon-α plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: A pilot study

By Amato Robert   Rawat Anish  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 171-175

Springer Publishing Company

Access to resources Recommend Favorite

First-line sunitinib cost-effective alternative to interferon-α in renal cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 561, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Sunitinib cost-effective alternative to interferon-α in renal cancer

By  

Inpharma, Vol. 1, Iss. 1654, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Effects of Native Human Leukocyte Interferon-α and Recombinant Human Interferon-α on P3-X63-Ag8.653 Mouse Myeloma Cell Growth

By Plesničar A   Vidmar G   Štabuc B   Kores Plesničar B  

The Journal of International Medical Research, Vol. 37, Iss. 5, 2009-09 ,pp. : 1570-1576

Field House Publishing

Access to resources Recommend Favorite

Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy: A Cost-Minimization Analysis

By Ravasio Roberto   Ortega Cinzia   Sabbatini Roberto   Porta Camillo  

Clinical Drug Investigation, Vol. 31, Iss. 7, 2011-07 ,pp. : 507-517

Adis International

Access to resources Recommend Favorite